Welcome to our dedicated page for Intuitive Surgical SEC filings (Ticker: ISRG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Intuitive Surgical, Inc. (ISRG) SEC filings page on Stock Titan provides access to the company’s official disclosures filed with the U.S. Securities and Exchange Commission. As a Nasdaq-listed issuer headquartered in Sunnyvale, California, Intuitive uses these filings to report financial results, material events, and other information relevant to shareholders and regulators.
Among the key documents available are current reports on Form 8-K. Recent 8-K filings include items reporting quarterly financial results under Item 2.02, where Intuitive furnishes press releases detailing revenue, procedure growth on its da Vinci surgical systems and Ion endoluminal system, and changes in the installed base of systems. Another 8-K filing reports a change in the role of a senior executive under Item 5.02, illustrating how the company discloses updates related to its leadership structure.
Investors also use Intuitive’s SEC filings to follow information that may appear in annual reports on Form 10-K and quarterly reports on Form 10-Q, such as risk factor discussions, descriptions of the company’s business and technologies, and summaries of regulatory and market conditions affecting robotic-assisted surgery and minimally invasive care. While these specific forms are not reproduced in the provided excerpts, they are part of the broader filing set accessible through the SEC’s EDGAR system.
On Stock Titan, ISRG filings are paired with AI-powered summaries designed to explain the content and context of complex documents. These tools can help readers understand the significance of earnings releases, regulatory updates, or governance changes without reading every line of each filing. Users can also review filings that relate to financial reporting, such as exhibits containing press releases, and monitor how Intuitive communicates procedure trends, system placements, and other operational metrics to the market.
For investors researching Intuitive’s regulatory history, this page serves as a focused entry point to the company’s SEC disclosures, including 8-Ks that reference earnings announcements and other material developments.
Intuitive Surgical, Inc. is asking stockholders to vote at its virtual 2026 annual meeting on April 30, 2026, at 3:00 p.m. Pacific. Proposals include electing ten directors, an advisory vote on executive pay, ratifying PricewaterhouseCoopers as auditor, and approving changes to the 2010 Incentive Award Plan.
The proxy details a planned leadership transition in which longtime CEO Gary S. Guthart became Executive Chair and David J. Rosa was promoted to Chief Executive Officer and director. The Board emphasizes strong governance, with eight of ten nominees independent, a separate Chair and CEO, a lead independent director, annual elections, proxy access, and strict anti‑hedging and anti‑pledging rules.
Operationally, for 2025 Intuitive reported revenue of $10,064.7 million, up 21% from 2024, and income from operations of $2,945.5 million, up 25%. Total da Vinci and Ion procedures reached 3,297,100, up 19%, supported by a growing installed base and multiple new FDA and international clearances for its da Vinci and Ion platforms.
INTUITIVE SURGICAL INC EVP & Chief Medical Officer Myriam Curet exercised options and sold shares in a coordinated transaction. She exercised a non-qualified stock option for 105 shares of common stock at an exercise price of $229.39 per share, then sold the 105 shares of common stock on the same day at an average price of $493.95 per share. The sale was carried out under a pre-arranged Trading Plan that complies with SEC Rule 10b5-1 and expires on July 29, 2026, indicating the timing was pre-scheduled. After these transactions, she directly holds no common shares but indirectly holds 409 shares by trust and continues to hold 1,152 option shares, so the sale represents a relatively small portion of her overall equity exposure to the company.
Myriam Curet McAdams reported multiple sales of Common Stock via Form 144. The filing lists seven transactions between
Trades were executed through Morgan Stanley Smith Barney LLC and are identified as stock option exercise and subsequent sales on or about the listed dates.
Intuitive Surgical SVP Mark Brosius reported selling 1,293 shares of Common Stock in open-market transactions. He sold 648 shares at $490.19 per share on March 6, 2026, and 645 shares at $485.01 per share on March 9, 2026. After these sales, he directly holds 1,613 shares. The transactions were executed under a pre-arranged Trading Plan that complies with SEC Rule 10b5-1 and runs through February 14, 2027, indicating these sales were scheduled in advance rather than timed discretionarily.
Intuitive Surgical senior executive Mark Brosius reported open-market sales of company common stock. As SVP and Chief Manufacturing and Supply Chain Officer, he sold a total of 3,658 shares across three transactions on March 3, 4, and 5, 2026.
The sales were executed at weighted-average prices of about $488.10, $498.6804, and $495.20 per share, with detailed price ranges provided in the footnotes. After these transactions, he directly held 2,906 shares of Intuitive Surgical common stock. All sales took place under a Trading Plan that complies with SEC Rule 10b5‑1 and expires on February 14, 2027.
Mark Brosius reported sales of ISRG common stock under 10b5-1 plans. The filing lists multiple 10b5-1 sales including
The filing also lists securities to be sold as Performance Stock Units (522,
ISRG reports a sale notice by an insider and scheduled restricted stock unit dispositions. A 10b5-1 sale executed
Intuitive Surgical VP Corporate Controller Fredrik Widman reported planned share sales and RSU vesting activity. He sold 249 shares of common stock on February 27, 2026 at
These sales followed the vesting of 468 restricted stock units on February 28, 2026, which converted into the same number of common shares. To cover statutory tax withholding on the vesting, 233 shares of common stock were disposed of at
Intuitive Surgical EVP & Chief Medical Officer Myriam Curet reported net insider sales of common stock through a trust. A trust associated with her sold 4,728 shares on March 3, 2026 at an average price of
On March 2, 2026, a non-qualified stock option for 125 shares was exercised and converted into common stock at an exercise price of